PMID- 21577319
OWN - NLM
STAT- MEDLINE
DCOM- 20110816
LR  - 20211020
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 4
IP  - 4
DP  - 2011 Apr
TI  - Morphological heterogeneity of oral salivary gland carcinomas: a 
      clinicopathologic study of 41 cases with long term follow-up emphasizing the 
      overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade 
      adenocarcinoma.
PG  - 336-48
AB  - We analyzed 41 oral salivary gland carcinomas from consecutive 290 salivary gland 
      carcinoma database (14%) with emphasis on the histological spectrum and clinical 
      outcome of adenoid cystic carcinoma (ACC) and polymorphous low-grade 
      adenocarcinoma (PLGA). The cohort included 14 ACCs, 14 mucoepidermoid carcinomas 
      (MECs), 8 PLGAs, 3 adenocarcinomas, not otherwise specified and 2 acinic cell 
      carcinomas. Mean age was 48, 58 and 61 yrs for ACC, MEC and PLGA, respectively. 
      Eight patients (19.5%) died of tumor at a mean interval of 66.5 months. ACC and 
      PLGA showed similar mean age, gender distribution, predominant palatal 
      localization, nodal metastasis, perineural invasion and MIB-1 index. However, ACC 
      tended to show higher tumor stage and residual tumor (R1/R2) more frequently than 
      PLGA, but this was statistically not significant. ACC and PLGA showed overlapping 
      architectural patterns. However, ACCs displayed well organized basal-luminal 
      differentiation, highlighted by CK5/CK7 immunostaining. In contrast, PLGA showed 
      a disorganized histological and immunohistological pattern. C-Kit expression 
      (CD117) was common in ACC, generally mirroring that of CK7 and virtually lacking 
      in PLGA. Kaplan-Meier analysis demonstrated a similar clinical course for ACC and 
      PLGA with 5 years survivals of 87% and 80%, respectively. Fluorescence in situ 
      hybridization (FISH) performed on all 290 salivary carcinomas confirmed the 
      specificity of the translocation t (11; 19) for MEC and its absence in all other 
      carcinomas including ACC and PLGA. Our results emphasize the diversity of oral 
      salivary gland carcinomas and the overlapping clinicopathological features of ACC 
      and PLGA.
FAU - Schwarz, Stephan
AU  - Schwarz S
AD  - Department of Pathology, University of Erlangen, Germany. 
      Abbas.agaimy@uk-erlangen.de
FAU - Muller, Maximilian
AU  - Muller M
FAU - Ettl, Tobias
AU  - Ettl T
FAU - Stockmann, Philipp
AU  - Stockmann P
FAU - Zenk, Johannes
AU  - Zenk J
FAU - Agaimy, Abbas
AU  - Agaimy A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110418
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRT5 protein, human)
RN  - 0 (KRT7 protein, human)
RN  - 0 (Keratin-5)
RN  - 0 (Keratin-7)
RN  - EC 2.3.2.27 (MIB1 ligase, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
SB  - IM
MH  - Adenocarcinoma/chemistry/genetics/mortality/*pathology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Acinar Cell/pathology
MH  - Carcinoma, Adenoid Cystic/genetics/mortality/*pathology/therapy
MH  - Carcinoma, Mucoepidermoid/pathology
MH  - Cell Differentiation
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 19
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Keratin-5/analysis
MH  - Keratin-7/analysis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-kit/analysis
MH  - Salivary Gland Neoplasms/chemistry/genetics/mortality/*pathology/therapy
MH  - Time Factors
MH  - Translocation, Genetic
MH  - Ubiquitin-Protein Ligases/analysis
MH  - Young Adult
PMC - PMC3093058
OTO - NOTNLM
OT  - Oral salivary gland carcinoma
OT  - acinic cell carcinoma
OT  - adenoid cystic carcinoma
OT  - polymorphous low-grade adenocarcinoma
EDAT- 2011/05/18 06:00
MHDA- 2011/08/17 06:00
PMCR- 2011/04/18
CRDT- 2011/05/18 06:00
PHST- 2011/04/01 00:00 [received]
PHST- 2011/04/12 00:00 [accepted]
PHST- 2011/05/18 06:00 [entrez]
PHST- 2011/05/18 06:00 [pubmed]
PHST- 2011/08/17 06:00 [medline]
PHST- 2011/04/18 00:00 [pmc-release]
PST - ppublish
SO  - Int J Clin Exp Pathol. 2011 Apr;4(4):336-48. Epub 2011 Apr 18.